In this OncLive® My Treatment Approach program, Dr. Joshua Richter and Dr. Surbhi Sidana discuss the evolving treatment landscape for relapsed/refractory multiple myeloma, with a focus on BCMA-directed therapies, including antibody-drug conjugates (ADCs), CAR T-cell therapies, and bispecific antibodies. They examine how prior treatment exposure, refractoriness, disease biology, and patient preferences influence treatment selection and sequencing at relapse. The discussion reviews clinical evidence from the DREAMM-7 and DREAMM-8 trials and considers the relative efficacy, safety profiles, and practical considerations associated with different BCMA-directed approaches. Dr. Sidana also shares strategies for recognizing and managing belantamab mafodotin-associated ocular toxicity, including patient counseling, ophthalmic monitoring, dose modifications, and multidisciplinary coordination. The experts further explore infrastructure and supportive care requirements for delivering these therapies in community and academic settings. Through clinical scenarios, they address patient selection, treatment access, caregiver support, and emerging evidence for ADC-based combinations in newly diagnosed multiple myeloma.
Dr. Joshua Richter and Dr. Surbhi Sidana discuss factors that guide treatment selection at first relapse in relapsed/refractory multiple myeloma, including prior treatment exposure, refractoriness, duration of response, disease biology, and patient preferences.
Dr. Joshua Richter and Dr. Surbhi Sidana discuss the evolving role of belantamab mafodotin in relapsed/refractory multiple myeloma following its reapproval based on the DREAMM-7 trial and additional evidence from DREAMM-8. Dr. Sidana reviews the efficacy of belantamab-based combinations and considers how they compare with BCMA-directed CAR T-cell therapies and bispecific antibodies.
